Author: Jessica Shneider
Date: June 26, 2025

ImYoo recently announced its seed round, led by Corundum Systems Biology, with participation from PsyMed Ventures, Freeflow Ventures, Arben Ventures, Adam Draper, and Jared Hecht.

It’s an early but important marker in a much larger story: how we move from measuring the human body in static snapshots to understanding it as a dynamic, ever-changing system, across time, across context, and across individuals.

At CSB, we back platforms that can shift paradigms. ImYoo is doing just that: bringing high-dimensional, longitudinal immune profiling out of the lab and into people’s homes. It’s a rethinking of who drives discovery, and what kind of data we need to personalize health in any meaningful way.

Where the Momentum Is: At-Home Sampling, High-Dimensional Data, and AI

In healthcare, the most exciting “fast-moving water” right now is the convergence of at-home sampling, high-throughput molecular assays, and AI-driven analytics. ImYoo’s platform combines patient-collected blood kits with single-cell RNA sequencing and ultra-low-cost processing to generate the kind of longitudinal, high-dimensional data that has never before been accessible outside of specialized research centers.

But collecting lots of data isn’t enough. Healthcare still faces urgent challenges – namely, the 80% non-responder rate seen with blockbuster biologics, highlighting that genetics alone can’t solve treatment matching. ImYoo’s platform tackles this bottleneck by empowering patients to collect real-time, at-home molecular data, generating longitudinal, high-dimensional measurements that feed into large health models. This patient-driven, time-series data engine exemplifies the kind of best-in-class, versatile bio-data platform we look for in a seed-stage investment, with applications ranging from treatment matching and clinical trial optimization to biomarker discovery and new drug development.

Bridging Lab, Technology, and the End-User: A Team Culture Built on Collaboration

ImYoo’s founders, Tatyana Dobreva, PhD (CEO) and David Brown, PhD (CTO), both Caltech alumni and former NASA Jet Propulsion Laboratory engineers, started ImYoo with a personal mission: to build the tools they wished existed during Tatyana’s search for an autoimmune diagnosis.

They’ve since built a capital-efficient, laser-focused team with an unusually strong grasp of both bench science and system design. That culture of “everyone wears both hats” not only accelerates iteration, but it also yields tools that scientists actually want to use, and patients find intuitive. Today, ImYoo has built a comprehensive immune atlas from patient-derived samples – demonstrating data fidelity while laying the groundwork for larger-scale studies – and is already deploying its bespoke “cohort-in-a-box” model with academic partners. This pilot phase reflects ImYoo’s broader strategy: collapsing the decade-long lab-to-clinic timeline by turning patients into active participants in generating longitudinal, high-resolution molecular data.

Solving the Data Bottleneck: From Cross-Sectional Snapshots to Longitudinal Multi-Omics

Traditional healthcare data is a collection of static snapshots: one lab test here, one genetic panel there. But human biology is dynamic. Early signals of disease – whether immune dysregulation in autoimmune disorders or metabolic shifts preceding diabetes – can only be seen in longitudinal multi-omic profiles.

ImYoo’s technology breaks this bottleneck. Participants place a small arm-mounted instrument that, with a simple click, inserts micro-needles to draw minute blood samples at intervals defined by the study, ranging from several times a day for night-versus-day comparisons to once a month for long-term monitoring – then return the samples for analysis.

At the heart of ImYoo’s at-home workflow is a method, originated at Caltech, extracting high-resolution immune data from just a small volume of self-collected capillary blood. This innovation enables cost-efficient, longitudinal profiling using single-cell RNA sequencing (scRNA-seq) and multiplexed assays, making it possible to generate high-quality data outside traditional lab settings.

By capturing detailed time courses of gene expression, protein markers, and lipid signatures, ImYoo’s platform feeds real-world datasets into health models that can predict disease flare-ups, optimize drug dosing, and guide preventive interventions. This patient-driven, real-time data engine collapses the typical decade-long lab-to-clinic cycle, unlocking insights that could power the next generation of predictive health algorithms.

What Investing in ImYoo Really Means

Investing in ImYoo means backing a company that tackles one of healthcare’s greatest challenges – turning raw molecular data into actionable insights by:

●      Putting patients at the center of the data pipeline.

●      Building an end-to-end platform designed to maintain a competitive edge.

●      Cultivating collaboration between engineers, lab scientists, and patient advocates.

We’re proud to join ImYoo at the seed stage and look forward to powering the next era of predictive, personalized healthcare.

Learn more at imyoo.health